№ files_lp_3_process_7_090571
File format: docx
Character count: 4167
File size: 16 KB
A brief evaluation of the article "The Effects of Probiotics in Ulcerative Colitis" providing suggestions on graphical abstract, table placement, abbreviation list, and citation formatting according to journal standards.
Year:
2023
Region / City:
Not specified
Theme:
Probiotics, Ulcerative Colitis, Functional Foods
Document Type:
Article Evaluation Sheet
Organization:
Functional Foods in Health and Disease
Author:
Babak Tamizifar, Awat Feizi, Marzieh Rahim khorasani, Nazila Kassaian, Ali Zamanimoghadam, Shayan Arbabnia, Peyman Adibi Sede
Target Audience:
Researchers, Clinicians, Academics
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2024
Region / City:
London, Exeter
Topic:
Breast cancer prevention
Document Type:
Review
Organization / Institution:
The London Breast Institute, The Princess Grace Hospital, College of Medicine and Health, University of Exeter Medical School
Author:
Kinan Mokbel, Kefah Mokbel
Target Audience:
Healthcare professionals, researchers in oncology and nutrition
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Document type:
Prior authorization request letter
Medical specialty:
Gastroenterology
Condition:
Ulcerative colitis
Medication:
STELARA® (ustekinumab)
Request type:
Standard or expedited authorization
Intended recipient:
Medical Director of payer organization
Healthcare setting:
Hospital outpatient, outpatient clinic, private practice, or other
Purpose:
Formulary exception and coverage authorization
Supporting materials referenced:
Prescribing information, clinical guidelines, peer-reviewed literature
Source type:
Clinical administrative correspondence
Year:
2021
Region / City:
Beijing, China
Topic:
Colorectal cancer, Ulcerative colitis
Document type:
Case report
Authors:
Zhi Zhang, Peng-Fei Yu, Guo-Li Gu, Yu-Hui Zhang, Yu-Ming Wang, Zhi-Wei Dong, Hai-Rui Yang
Corresponding author:
Guo-Li Gu
Patient age:
31 years
Diagnosis:
Diffuse invasive signet ring cell carcinoma of colorectum
Treatment:
Laparoscopic total colorectal resection, ileal pouch–anal anastomosis, ileostomy, FOLFOX + cetuximab chemotherapy
Outcome:
Patient deceased after 7 months due to tumor progression and multiple organ dysfunction
Funding:
Beijing Capital Medical Development Research Fund, No. Shoufa2020-2-5122
Keywords:
Ulcerative colitis; Colorectal cancer; Signet ring cell carcinoma; Case report
Clinical presentation:
Mucopurulent bloody stools, abdominal distension
Histopathology:
Rectal mucinous adenocarcinoma, confirmed SRCC
Genetic testing:
Tumor mutational burden 26.2/Mb
Year:
2022
Region / City:
Kolkata, India
Topic:
Intestinal parasitic co-infection, Segmental colitis
Document Type:
Case Report
Institution:
Institute of Post Graduate Medical Education & Research, SSKM Hospital, Kolkata
Authors:
Dr. Sanchari Bairagya, Dr. Dipankar Paul, Dr. Kumkum Bhattacharyya
Target Audience:
Medical professionals, researchers, students in microbiology and gastroenterology
Date of Approval:
2022
Date of Modification:
Not specified
Keywords:
Protozoa, Helminths, Co-infection, Segmental colitis, Giardia intestinalis, Hymenolepis nana, Strongyloides stercoralis
Study duration:
12 weeks
Location:
South Carolina, United States
Clinical site:
Prisma Health IBD Clinic
Participating institution:
University of South Carolina
Medical specialty:
Gastroenterology
Disease focus:
Ulcerative colitis
Intervention:
American Ginseng
Study design:
Double-blind placebo-controlled clinical trial
Planned sample size:
80 participants
Lead clinical collaborator:
Dr. Joseph Meserve
Participant population:
Adults aged 18 years and older with confirmed ulcerative colitis on stable 5-ASA therapy
Primary recruitment source:
Prisma Health Gastroenterology and Hepatology patient database
Recruitment coordination:
USC research team and Prisma Health staff
Inclusion criteria:
Confirmed ulcerative colitis diagnosis, UCDAI score greater than 3, stable 5-ASA therapy, informed consent
Exclusion criteria:
Crohn’s disease or other IBD conditions, biologic or small molecule immunotherapy use, pregnancy or breastfeeding, active infection, active malignancy, investigational drug participation, ginseng allergy, medications causing interaction risks
Participant compensation:
Up to $200 via Visa gift cards
Data collection:
Blood, stool, and urine samples
Recruitment methods:
Patient database identification, physician referrals, brochures and flyers, clinic outreach, online announcements
Retention measures:
Participant education, regular communication, flexible scheduling, incentives, community engagement
Year:
2024
Region / Country:
Australia
Therapeutic Area:
Gastroenterology
Type of Document:
Regulatory submission / PBAC evaluation
Product:
Budesonide 4 mg suppository (Budenofalk®)
Comparator:
Budesonide 2 mg foam (Budenofalk®), prednisolone suppositories and enemas, hydrocortisone acetate enemas
Regulatory Authority:
TGA (Therapeutic Goods Administration)
Intended Use:
Short-term treatment of mild to moderate ulcerative colitis limited to the rectum
Prescriber Type:
Medical practitioners, Nurse practitioners
PBS Benefit Type:
Unrestricted
Maximum Quantity:
1 pack, 30 units
Treatment Duration:
up to 8 weeks per script
Clinical Evidence:
Phase 3, randomized, double-blind, double-dummy, non-inferiority trial (BUS-4/UCA)
Document type:
Prior authorization request letter
Medical specialty:
Gastroenterology
Condition:
Ulcerative colitis
Medication:
STELARA® (ustekinumab)
Request type:
Standard or expedited authorization
Intended recipient:
Medical Director of payer organization
Healthcare setting:
Hospital outpatient, outpatient clinic, private practice, or other
Purpose:
Formulary exception and coverage authorization
Supporting materials referenced:
Prescribing information, clinical guidelines, peer-reviewed literature
Source type:
Clinical administrative correspondence
Year:
1986
Region / city:
Global
Topic:
Fisheries, Fish Disease
Document type:
Scientific report
Organization / institution:
Food and Agriculture Organization of the United Nations (FAO)
Author:
FAO
Target audience:
Researchers, fishery professionals, veterinarians
Period of validity:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Note:
Context description
Year:
2021
Region / City:
Beijing, China
Topic:
Colorectal cancer, Ulcerative colitis
Document type:
Case report
Authors:
Zhi Zhang, Peng-Fei Yu, Guo-Li Gu, Yu-Hui Zhang, Yu-Ming Wang, Zhi-Wei Dong, Hai-Rui Yang
Corresponding author:
Guo-Li Gu
Patient age:
31 years
Diagnosis:
Diffuse invasive signet ring cell carcinoma of colorectum
Treatment:
Laparoscopic total colorectal resection, ileal pouch–anal anastomosis, ileostomy, FOLFOX + cetuximab chemotherapy
Outcome:
Patient deceased after 7 months due to tumor progression and multiple organ dysfunction
Funding:
Beijing Capital Medical Development Research Fund, No. Shoufa2020-2-5122
Keywords:
Ulcerative colitis; Colorectal cancer; Signet ring cell carcinoma; Case report
Clinical presentation:
Mucopurulent bloody stools, abdominal distension
Histopathology:
Rectal mucinous adenocarcinoma, confirmed SRCC
Genetic testing:
Tumor mutational burden 26.2/Mb
Year:
2025
Region / city:
Karaganda, Kazakhstan
Topic:
Medical research, endoscopic hemostasis
Document type:
Research article
Institution:
NCJSC "Medical University Karaganda"
Author:
Abatov N.T., Badyrov R.M., Rymtaeva M.S., Balgabekkyzy T.A., Zhaksylyk E.K.
Target audience:
Medical professionals, researchers, healthcare specialists
Period of validity:
N/A
Date of approval:
N/A
Date of changes:
N/A
Study duration:
12 weeks
Location:
South Carolina, United States
Clinical site:
Prisma Health IBD Clinic
Participating institution:
University of South Carolina
Medical specialty:
Gastroenterology
Disease focus:
Ulcerative colitis
Intervention:
American Ginseng
Study design:
Double-blind placebo-controlled clinical trial
Planned sample size:
80 participants
Lead clinical collaborator:
Dr. Joseph Meserve
Participant population:
Adults aged 18 years and older with confirmed ulcerative colitis on stable 5-ASA therapy
Primary recruitment source:
Prisma Health Gastroenterology and Hepatology patient database
Recruitment coordination:
USC research team and Prisma Health staff
Inclusion criteria:
Confirmed ulcerative colitis diagnosis, UCDAI score greater than 3, stable 5-ASA therapy, informed consent
Exclusion criteria:
Crohn’s disease or other IBD conditions, biologic or small molecule immunotherapy use, pregnancy or breastfeeding, active infection, active malignancy, investigational drug participation, ginseng allergy, medications causing interaction risks
Participant compensation:
Up to $200 via Visa gift cards
Data collection:
Blood, stool, and urine samples
Recruitment methods:
Patient database identification, physician referrals, brochures and flyers, clinic outreach, online announcements
Retention measures:
Participant education, regular communication, flexible scheduling, incentives, community engagement